SMURF-Therapeutics, Inc. is developing small molecule therapeutics to activate or block Smurf2 for cancer, anemia and wound healing. The company was founded by Wafik El-Deiry, MD, PhD, FACP in 2021 to develop small molecule compounds targeting hypoxia responses based on numerous academic research papers and reviews published over 3 decades.